Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I

Current Neuropharmacology

Volumn 7, Issue 4, 2009, Pages 302-314

  Miller, R ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Antipsychotic drugs; Atypical antipsychotic agents; Cholinergic interneurones; D1 receptors; D2 receptors; Muscarinic M1 receptors; Muscarinic M4 receptors; Neuroleptic drugs; Neuroleptic threshold

Indexed keywords

ACETYLCHOLINE; ALKALOID DERIVATIVE; ATROPINE; ATYPICAL ANTIPSYCHOTIC AGENT; BROMPERIDOL; CHLORPROMAZINE; CHLORPROTHIXENE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; CYCLIC AMP; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DROPERIDOL; FLUPERLAPINE; FLUPHENAZINE; GALANTAMINE; HALOPERIDOL; LEVODOPA; MESORIDAZINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M4 RECEPTOR; NEUROLEPTIC AGENT; NEUROTRANSMITTER; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; THIORIDAZINE; UNINDEXED DRUG;

ACETYLCHOLINE RELEASE; CATALEPSY; CHOLINERGIC SYSTEM; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SENSITIVITY; DRUG TARGETING; HUMAN; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; PSYCHOSIS; REINFORCEMENT; REVIEW; STRIATE CORTEX; TARDIVE DYSKINESIA;

EID: 73649108863     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157015909790031229     Document Type: Review

References (161)

1. Andersen, M.B., Fink-Jensen, A., Peacock, L., Gerlach, J., Bymaster, F., Lundbaeck, J.A., Werge,T. (2003) The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys. Neuropsychopharmacology, 28, 1168-1175.
2. Andersen, M.B., Werge, T., Fink-Jensen A. (2007) The acetylcholinesterase inhibitor galantamine inhibits d-amphetamine-induced psychotic-like behavior in Cebus monkeys. J. Pharmacol. Exp. Ther., 321, 1179-1182.
3. Andersen, P.H., Gronvald, F.C., Jansen,J.A. (1985) A comparison between dopamine-stimulated adenylate cyclase and 3H-SCH 23390 binding in rat striatum. Life Sci., 37,1971-1983.
4. Andersen, P.H. (1988) Comparison of the pharmacological characteristics of [3H] raclopride and [3H]SCH23390 binding to dopamine receptors in vivo in mouse brain. Eur. J. Pharmacol., 146,113-120.
5. Angus, J.W.S., Simpson,G.M. (1970) Handwriting changes and response to drugs: A controlled study. Acta Psychiatr. Scand. Suppl., 212, 28-37.
6. Anzou, P., Özsancak, C., Hannquin, D., Moore, N., Augustin, P. (1986) Clozapine for the treatment of psychosis in Parkinson's disease. Acta Neurol. Scand., 94, 329-336.
7. Ariano, M.A., Kang, H.C., Haugland, R.P., Sibley, D.R. (1991) Multiple fluorescent ligands for dopamine receptors. II: Visualization in neural tissues. Brain Res., 547,208-222.
8. Beninger, R.J. (1983) The role of dopamine in locomotor behavior and learning. Brain Res. Brain Res. Rev., 6, 173-196.
9. Beninger, R.J., Miller, R. (1998) Dopamine D1-like receptors and reward-related incentive learning. Neurosci. Biobehav. Rev., 22, 335-345.
10. Beninger, R.J., Nakonechny, P.L., Todd, M.J. (1996) Inhibition of protein kinase A in the nucleus accumbens blocks amphetamine-produced conditioned place preference in rats. Abstr. Soc. Neurosci., 22, 1127.
11. Bennett, J.P., Landow, E.R., Dietrich, S., Schuh,L.A. (1994) Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction. Mov. Disord., 9, 409-414.
12. Bernardo, M., Parellada, E., Lomeña, F., Catafau, A.M., Font, M., Gómez, J.C., López-Carrero, C., Gutiérrez, F., Pavla, J., Salamero, M. (2001) Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint [I123]IBZM SPECT study. Psychiatry Res., 107, 87-97.
13. Bolden, C., Cusack, B., Richelson, E. (1992) Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J. Pharmacol. Exp. Ther., 260, 576-580.
14. Bonner, T.I., Buckley, N.J., Young, A.C., Brann, M.R. (1987) Identification of a family of muscarinic acetylcholine receptor genes. Science, 237, 527-532.
15. Bonner, T.I., Young, A.C., Brann, M.R., Buckley, N.J. (1988) Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor gene. Neuron, 1, 403-410.
16. Brené, S., Lindefors, N., Herrera-Marschitz, M., Persson, H. (1990) Expression of dopamine D2 receptor and choline acetyltransferase mRNA in the dopamine deafferented rat caudate-putamen. Exp. Brain Res., 83, 96-104.
17. Bymaster, F.P., Calligaro, D.O., Falcone, J.F., Marsh, R.D., Moore, N.A., Tye, N.C., Seeman, P. Wong, D.T. (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology, 14, 87-96.
18. Bymaster, F.P., Felder, C.C., Tzavara, E., Nomikos, G.G., Calligaro, D.O., Mckinzie, D.L. (2003) Muscarinic mechanisms of antipsychotic atypicality. Prog. Neuropsychopharmacol. Biol. Psychiatry, 27, 1125-1143.
19. Caroff, S.N., Martine, R., Kleiner-Fisman, G., Eisa, M., Lorry, A., Gallop, R., Stern, M.B., Duda, J.E. (2006) Treatment of levodopa-induced dyskinesias with donezepil. Parkinsonism Relat. Disord., 12, 261-263.
20. Chen, M.T., Morales, M., Woodward, D.J., Hoffer, B.J., Janak, P.H. (2001) In vivo extracellular recording of striatal neurons in the awake rat following unilateral 6-hydroxydopamine lesions. Exp. Neurol., 171, 72-83.
21. Choi, S., Haggart, D., Lawrence, T., Cuny, G.D. (2004) Synthesis, receptor binding and functional studies of mesoridazine stereoisomers. Bioorg. Med. Chem. Lett., 14, 4379-4382.
22. Chouinard, G. (1990) Severe cases of neuroleptic-induced supersensitivity psychosis, diagnostic criteria for the disorder and its treatment. Schizophr. Res., 5, 21-33.
23. Chouinard, G., Jones, B.D. (1980) Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am. J. Psychiatry, 137, 16-21.
24. Chouinard, G., Miller, R. (1999a) A rating scale for psychotic symptoms (RSPS): Part I: theoretical principles and subscale 1: perception symptoms (illusions and hallucinations) Schizophr. Res., 38, 101-122.
25. Chouinard, G., Miller, R. (1999b) A rating scale for psychotic symptoms (RSPS): Part II: Subscale 2: distraction symptoms (catatonia and passivity experiences); subscale 3: delusions; and semistructured interview (SSCI-RSPS) Schizophr. Res., 38, 123-150.
26. Chouinard, G., Jones, B.D., Annable, L. (1978) Neuroleptic-induced supersensitivity psychosis. Am. J. Psychiatry, 135, 1409-1410.
27. Copolov, D.L., Link, C.G., Kowalcyk, B.A. (2000) A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia. Psychol. Med., 30, 95-105.
28. Coppens, H.J., Sloogg, C.J., Paans, A.M.J., Wiegman, T., Vaalburg, W., Korf, J. (1991) High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients. Biol. Psychiatry 29, 629-634.
29. Cotzias, G.C., Papavasiliou, P.S., Gellene, R. (1969) Modification of parkinsonism: chronic treatment with L-DOPA. N. Engl. J. Med., 280, 337-345.
30. Creese, I., Burt, D.R., Snyder, S.H. (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science, 192, 481-483.
31. Dains, K., Hitzemann, B., Hitzemann, R. (1996) Genetics, neuroleptic response and the organization of cholinergic neurons in the mouse striatum. J. Pharmacol. Exp. Ther., 279, 1430-1438.
32. Dawson, V.L., Dawson, T.M., Filloux, F.M., Wamsley, J.K. (1988) Evidence of dopamine D2 receptors on cholinergic interneurons in the rat caudate putamen. Life Sci., 42, 1933-1939.
33. De Beaurepaire, R., Labelle, A., Naber, D., Jones, B.D., Barnes, T.R.E. (1995) An open trial of the D1 antagonist SCH 39166 in six cases of acute psychotic states. Psychopharmacology (Berl), 121, 323-337.
34. Den Boer, J.A., van Megen, H.J.G.M., Fleischhacker, W.W., Louwerens, J.W., Slaap, B.R., Westenberg, H.G.M., Burrows, G.D., Srivasta, O.N. (1995) Differential effects of the D1-DA receptor antagonist SCH 39166 on positive and negative symptoms of schizophrenia. Psychopharmacology (Berl), 121, 317-322.
35. DiFiglia, M. (1987): Synaptic organization of cholinergic neurons in the monkey striatum. J. Comp. Neurol., 255, 245-258.
36. Durif, F., Vidailhet, M., Assal, F., Roche, C., Bonnet, A.M., Agid, Y. (1997) Low-dose clozapine improves dyskinesias in Parkinson's disease. Neurology, 48, 658-662.
37. Durif, F., Debilly, B., Galitzky, M., Morand, D., Viallet, F., Borg, M., Thobois, S., Broussolle, E., Rascol, O. (2004) Clozapine improves dyskinesias in Parkinson disease: a double-blind placebo-controlled study. Neurology, 62, 381-388.
38. Ellis, T., Cudkowicz, M.E., Sexton, P.M., Growdon,J.H. (2000) Clozapine and risperidone treatment of psychosis in Parkinson's disease. J. Neuropsychiatry Clin. Neurosci., 12, 364-369.
39. Engelhardt, D.M., Rosen, B., Freedman, N., Margolis, R. (1967) Phenothiazines in prevention of psychiatric hospitalization - a reevaluation. Arch. Gen. Psychiatry 16, 98-101.
40. Factor, S.A., Friedman, J.H., Lannon, M.C., Oakes, D., Bourgeois, K. and the Parkinson Study Group. (2001) Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov. Disord., 16, 135-139.
41. Farde, L., Nordström, A.-L., Wiesel, F.-A., Pauli, S., Halldin, C., Sedvall, G. (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch. Gen. Psychiatry 49, 538-544.
42. Fischer, P., Danielczyk, W., Simanyi, M., Streifler, M.B. (1990) Dopaminergic psychoses in advanced Parkinson's disease. Adv. Neurol., 53, 391-397.
43. Fitzgerald, P.B., Kapur, S, Remington, G., Roy, P., Zipursky, R.B. (2000) Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels. Psychopharmacology (Berl), 149, 1-5.
44. Forssman, A., Ohman, R. (1976) Pharmacokinetic studies on haloperidol in man. Curr. Ther. Res., 20, 319-336.
45. Frankle, W.G., Gil, R., Hacket, E., Mawlawi, O., Zea-Ponce, Y., Zhu, Z., Kochan, L.D., Cangiano, C., Slifstein, M., Gorman, J.M., Laruelle, M., Abi-Dargham, A. (2004) Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications. Psychopharmacology (Berl), 175, 473-480.
46. Geaney, D.P., Ellis, P.M., Soper, N., Shepstone, B.J., Cowen, P.J. (1992) Single photon emission tomography assessment of cerebral dopamine D2 receptor blockade in schizophrenia. Biol. Psychiatry, 32, 293-293.
47. Glick, I.D., Berg, P.H. (2002) Time to study discontinuation, relapse and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders. Int. Clin. Psychopharmacol., 17, 65-68.
48. Gomeza, J., Shannon, H., Kostenis, E., Felder, C., Zhang, L., Brodkin, J., Grinberg, A., Sheng, H., Wess, J. (1999) Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice. Proc. Natl. Acad. Sci., USA, 96, 1692-1697.
49. Haase, H.-J. (1954) Über das Vorkommen und Deutung des psychomotorischen Parkinsonsyndroms bei Megaphen bzw. Largactil-Dauerbehandlung. Nervenarzt, 25, 586-592.
50. Haase, H.-J. (1965) Clinical Observations on the Actions of Neuroleptics. In: Haase, H.-J, Janssen, P.A.J. Eds, Actions of Neuroleptic Drugs: A Psychiatric, Neurological and Pharmacological Investigation. Amsterdam, N. Holland, pp.1-98.
51. Haase, H.-J., Kaumeier, S., Schwarz, H., Gundei, A., Linde, O.K., Maetz, H., Scheel, R., Stripf, A. Stripf, L. (1978) Open study with bromperidol (C-C 2489), a new neuroleptic, for the determination of the neuroleptic threshold and the neuroleptic therapeutic range. Pharmakopsychiatry, 11, 81-85.
52. Haase, H.-J., Kaumeier, S., Schwarz, S., Gundel, A., Libde, O.K., Höness V. R., Bomhard, E.R., Rauwolf, E.R., Schel, R., Seyfferth, H., Stripf, A., Stripf, L. (1980) Clinical trial of droperidol for the determination of the neuroleptic threshold and the neuroleptictherapeutic range. Int. Pharmacopsychiatry, 15, 74-80.
53. Haddad, P.M., Wieck, A. (2004) Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs, 64, 2291-2314.
54. Heresco-Levy, U., Greenburg, D., Lerer, B., Dasberg, H., Brown, W.A. (1993) Trial of maintenance neuroleptic dose reduction in schizophrenic outpatients: two-year outcome. J. Clin. Psychiatry, 54, 59-62.
55. Herrting, G., Zumstein, A., Jakisch, R., Hoffman, R., Starke, K. (1980). Modulation by endogenous dopamine of the release of acetylcholine in caudate nucleus of the rabbit. Naunyn Schmiedebergs Arch. Pharmacol., 315, 111-117.
56. Hersch, S.M., Gutekunst, C.A., Rees, H.D., Heilman, C.J., Levey, A.I. (1994) Distribution of m1-m4 muscarinic receptor proteins in the rat striatum: light and electron microscopic immunocytochemistry using subtype-specific antibodies. J. Neurosci., 14, 3351-3363.
57. Hippius, H. (1976) On the Relations Between Antipsychotic and Extrapyramidal Effects of Psychoactive Drugs. In: Sedvall, G., Uvnas, B., Zotterman, Y. Eds, Antipsychotic Drugs: Pharmacodynamics and Pharmacokinetics (Werner-Gren International Symposium Series, vol. 25), Oxford, Pergamon Press, pp. 437-445.
58. Hirsch, S., Bowen, J., Emami, J., Cramer, P., Jolley, A., Haw, C., Dickinson, M. (1996) A one-year prospective study of the effect of life events and medication in the aetiology of schizophrenic relapse. Br. J. Psychiatry, 168, 49-56.
59. Hitzemann, R., Qian, Y., Hitzemann, B. (1993) Dopamine and acetylcholine cell density in the neuroleptic responsive (NR) and neuroleptic nonresponsive (NNR) lines of mice. J. Pharmacol. Exp. Ther., 266, 431-438.
60. Hogarty, G.E., McEvoy, J.P., Munetz, M., Barry, A.L.D., Bartone, P., Cather, R., Cooley, S.J., Urich, R.F., Carter, M., Madonia, M.J. (1988) Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Arch. Gen. Psychiatry, 45, 797-805.
61. Holt, D.J., Herman, M.M., Hyde, T.M., Kleinman, J.E., Sinton, C.M., German, D.C., Hersh, L.B., Graybiel, A.M., Saper, C.B. (1999) Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia. Neuroscience, 94, 21-31.
62. Holt, D.J., Bachus, S.E., Hyde, T.E., Wittie, M., Herman, M.M., Vangel, M., Saper, C.B., Kleinman, J.E. (2005) Reduced density of cholinergic interneurons in the ventral striatum in schizophrenia: an in situ hybridization study. Biol. Psychiatry, 58, 408-416.
63. Horstink, M.W.I.M., Zijlmans, J.C., Pasman, J.W., Berger, H.J., van't Hof, M.A. (1990) Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. J. Neurol. Neurosurg. Psychiatry., 53, 224-226.
64. Hyttel, J. (1983) SCH 23390 - The first selective dopamine D-1 antagonist. Eur. J. Pharmacol., 91, 153-154.
65. Ince, E., Ciliax, B.J., Level, A.I. (1997) Differential expression of D1 and D2 dopamine and M4 muscarinic acetylcholine receptor proteins in identified striatonigral neurons. Synapse, 27, 357-366.
66. Janowsky, D.S. (2005) Minimally effective doses of conventional antipsychotic medications used to treat aggression, and self-injurious behaviors in mentally retarded adults. J. Clin. Psychopharmacol., 25,19-25.
67. Janowsky, D.S., El-Yousef, M.K., Davis, J.M., Selerke, H.J.. (1973) Antagonistic effects of physostigmine and methylphenidate in man. Am. J. Psychiatry 130, 1370-1376.
68. Joyce, J.N., Marshall, J.F. (1985) Striatal topography of D2 receptors correlates with indexes of cholinergic neuron localization. Neurosci. Lett., 53, 127-131.
69. Kane, J.M., Rifkin, A., Woerner, M. Reardon, G., Sarantakos, S., Schiebel, D., Ramirez, I. (1983) Low-dose neuroleptic treatment of outpatient schizophrenics. I: Preliminary results for relapse rates. Arch. Gen. Psychiatry, 40, 893-896.
70. Kane, J.M., Honigfeld, G., Singer, J., Meltzer, H. and the Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic. Arch. Gen. Psychiatry, 45, 789-796.
71. Kanes, S.J., Hitzemann, B.A., Hitzemann, J. (1993) On the relationship between D2 receptor density and neuroleptic-induced catalepsy among eight inbred strains of mice. J. Pharmacol. Exp. Ther., 267, 538-547.
72. Kapur, S., Zipursky, R., Jones, C., Remington, G., Houle, S. (2000) Relationship between D(2) occupancy and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 157, 514-520.
73. Karle, J., Clemmensen, L., Hansen, L., Andersen, M., Andersen, J., Fensbo, C., Sloth-Nielsen, M., Lublin, H., Gerlach, J. (1995) NNC-01-0687, a selective dopamine receptor antagonist, in the treatment of schizophrenia. Psychopharmacology (Berl), 121, 328-329.
74. Karlsson, P., Smith, L., Farde, L., Harnryd, C., Sedvall, G., Wiesel, F.A. (1995b) Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology (Berl), 121, 309-316.
75. Kasper, S., Muller-Spahn, F. (2000) Review of quetiapine and its clinical applications in schizophrenia. Exp. Opin. Pharmacother., 1, 783-801.
76. Kempster, P.A., Gibb, W.R., Stern, G.M., Lees,A.J. (1989) Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations. J. Neurol. Neurosurg. Psychiatry., 52, 72-76.
77. Kerr, J.N., Wickens, J.R. (2001) Dopamine D-1/D-5 receptor activation is required for long-term potentiation in the rat neostriatum in vitro. J. Neurophysiol., 85, 117-124.
78. Kessler, R.M., Ansari, A.S., Riccardi, P., Li, R., Jayathilake, K., Dawant, B., Meltzer, H.Y. (2006) Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology, 31,1991-2001.
79. Kish, L.J., Palmer, M.R., Gerhardt, G.A. (1999) Multiple single-unit recordings in the striatum of freely moving animals: effects of apomorphine and d-amphetamine in normal and unilateral 6-hydroxydopamine-lesioned rats. Brain Res., 833,58-70.
80. Klemm, W.R. (1965) Potentiation of animal "hypnosis" with low levels of electric current. Anim. Behav., 13, 571-574.
81. Klemm, W.R. (1983) Experimental catalepsy: influences of cholinergic transmission in restraint-induced catalepsy. Experientia, 39, 228-230.
82. Küfferle, B., Tauscher, J., Asenbaum, S., Vesely, C., Podreka, I., Brücke, T., Kasper, S. (1997) IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. Psychopharmacology (Berl.), 133, 323-328.
83. Küstner, U., Müller-Oerlinghausen,B. (1985) The handwriting test as an aid to neuroleptic dose. Int. J. Clin. Pharmacol. Ther. Toxicol., 23 (Suppl 1), S34-41.
84. Lehmann J., Langer, S.Z. (1983): The striatal cholinergic interneuron: synaptic target of dopaminergic terminals? Neuroscience, 4, 1105-1120.
85. Leysen, J.E., Niemegeers, C.J.E., Tollenaere, J.P., Laduron, P.M. (1978) Serotonergic component of neuroleptic receptors. Nature, 272, 168-171.
86. Leysen, J.-E., Gommeren, W., Eens, A., de Chaffoy de Courcelles, D., Stoof, J.C., Janssen, P.A.J. (1988) Biochemical profile of risperidone, a new antipsychotic. J. Pharmacol. Exp. Ther., 247, 661-670.
87. Lindenmayer, J.P., Smith, D., Katz, I. (1984) Radioreceptor assay of neuroleptics in refractory chronic schizophrenic patients. J. Clin. Psychiatry, 45, 117-119.
88. Lloyd, K.G., Mohler, H., Heitz, P., Bartholini, G. (1975) Distribution of choline acetyltransferase and glutamate decarboxylase within the substantia nigra and in other brain regions from control and parkinsonian patients. J. Neurochem., 25, 789-795.
89. Loopuijt, L.D. (1989) Distribution of dopamine D-2 receptors in the rat striatal complex and its comparison with acetylcholinesterase. Brain Res. Bull., 22, 805-817.
90. Marder, S.R., Van Putten, T., Mintz, J., McKenzie, J., Lebell, M., Faltico, G., May, P.R.A. (1984) Costs and benefits of two doses of fluphenazine. Arch. Gen. Psychiatry, 41, 1025-1029.
91. McEvoy, J.P., Stiller, R.L., Farr,R. (1986) Plasma haloperidol levels drawn at neuroleptic threshold doses: a pilot study. J. Clin. Psychopharmacol., 6, 133-138.
92. McEvoy, J.P., Butner, N.C., Hogarty, G.E., Steingard, S. (1991) Optimal dose of neuroleptic in acute schizophrenia: a controlled study of neuroleptic threshold and higher haloperidol dose. Arch. Gen. Psychiatry, 48, 739-735.
93. McGraw, C.P., Klemm, W.R. (1973) Genetic differences in susceptibility of rats to the immobility reflex: "Animal hypnosis". Behav. Genet., 3, 155-162.
94. McQuade, R.D., Duffy, R.A., Coffin, V.L., Barnett, A. (1992) In vivo binding to dopamine receptors: a correlate of potential antipsychotic activity. Eur. J. Pharmacol., 215, 29-34.
95. Melkersson, K. (2005) Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J. Clin. Psychiatry 66, 761-767.
96. Meltzer, H.Y., Matsubara, S., Lee, J.-C. (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D2 and serotonin-2 pKi values. J. Pharmacol. Exp. Ther., 251, 238-245.
97. Miller, R. (1976) Schizophrenic psychology, associative learning and the role of forebrain dopamine. Med. Hypotheses, 2, 203-211.
98. Miller, R. (1984) Major psychosis and dopamine: controversial features and some suggestions. Psychol. Med., 14, 779-791.
99. Miller, R. (1987) The time course of neuroleptic action for psychosis: role of learning processes and implications for concepts of psychotic illness. (A Review) Psychopharmacology (Berl.), 92, 405-415.
100. Miller, R. (1993) Striatal dopamine in reward and attention: a system for understanding symptomatology of acute schizophrenia and mania. Int. Rev. Neurobiol., 35, 161-278.
101. Miller, R. (1997) Dose-response relationships for the antipsychotic effects and Parkinsonian side-effects of typical neuroleptic drugs: Practical and theoretical implications. Prog. Neuropsychopharmacol. Biol. Psychiatry, 21, 1059-1094.
102. Miller, R. (2008a) A Theory of the Basal Ganglia and their Disorders. (Conceptual Advances in Brain Research series), Taylor and Francis, London.
103. Miller, R. (2008b) A Neurodynamic Theory of Schizophrenia and Related Disorders. Morrinsville, North Carolina, Lulu Enterprises, Inc. (details: www.robertmiller-octspan.co.nz).
104. Miller, R., Chouinard, G. (1993) Loss of striatal cholinergic neurons as a basis for tardive and L-Dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol. Psychiatry, 34, 713-738.
105. Miller, R., Wickens, J.R., Beninger, R.J. (1990) Dopamine D-1 and D-2 receptors in relation to reward and performance: a case for the D-1 receptor as a primary site of therapeutic action of neuroleptic drugs. Prog. Neurobiol., 34, 143-184.
106. Mizrahi, R., Kiang, M., Mamo, D.C., Arenovich, T., Bagby, R.M., Zipursky, R.B., Kapur, S. (2006) The selective effect of antipsychotics on the different dimensions of the experience of psychosis in schizophrenia spectrum disorders. Schizophr. Res., 88, 111-118.
107. Mones, R.J. (1972) L-Dopa-induced dyskinesias in normal rhesus monkey. Mt. Sinai J. Med., 39, 197-201.
108. Mones, R.J. (1973) Experimental Dyskinesias in Normal Rhesus Monkey. In: Barbeau, A. Chase, T.N., Paulson, G.E. Eds, Adv. Neurol., Vol 1, New York, Raven Press, New York, pp. 665-669.
109. Mones, R.J., Elizan, T.S., Siegel, G. (1971) Analysis of L-DOPA induced dyskinesias in 51 patients with parkinsonism. J. Neurol. Neurosurg. Psychiatry., 34, 668-673.
110. Nisenbaum, E.S., Stricker, E.M., Zigmon, M.J., Berger, T.W. (1986) Long-term effects of dopamine-depleting lesions on spontaneous activity of type II striatal neurons: relation to behavioural recovery. Brain Res., 398, 221-230.
111. Nishikawa, T., Tsuda, A., Tanaka, M., Koga, I., Ushida, Y. (1982) Prophylactic effects of neuroleptics in symptom-free schizophrenics: roles of dopaminergic and noradrenergic blockers. Biol. Psychiatry 20, 1161-1166.
112. Nordberg, A., Nyberg, P., Windblad, B. (1985) Topographic distribution of choline acetyltransferase activity and muscarinic and nicotinic receptors in Parkinson brains. Neurochem. Pathol., 3, 223-236.
113. Nordström, A.L., Farde, L., Wiesel, F.A., Forslund, K., Pauli, S., Halldin, C., Uppfeldt, G. (1992) Central D2-dopamine receptor occupancy in relation to antipsychotic drugs effects: a double-blind PET study of schizophrenic patients. Biol. Psychiatry, 33, 227-235.
114. Nyberg, S., Eriksson, B., Oxenstierna, G., Halldin, C., Farde, L. (1999) Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2a receptor occupancy in schizophrenic patients. Am. J. Psychiatry, 156, 869-875.
115. Olianas, M.C., Adem, A., Karlsson, E., Onali, P. (1996) Rat striatal muscarinic receptors coupled to the inhibition of adenylyl cyclase activity: potent block by the selective M4 ligand muscarinic toxin 3 (MT3). Br. J. Pharmacol., 116, 283-288.
116. Olianas, M.C. Adem, A., Karlsson, E., Onali, P. (1998) Identification of rat brain muscarinic M4 receptors coupled to cyclic AMP using the selective antagonist muscarinic toxin 3. Eur. J. Pharmacol., 357, 235-242.
117. Olsson,H., Farde,L. (2005) Half-life of receptor occupancy - a meaningless concept. Int. J. Neuropsychopharmacol., 8, 141-142.
118. Onali, P., Olianas, M.C. (2002) Muscarinic M4 receptor inhibition of dopamine D1-like receptor signalling in rat nucleus accumbens. Eur. J. Pharmacol., 448, 105-111.
119. Passero, S., Carli, G., Battistini, N. (1981) Depression of cerebral glucose utilization during animal hypnosis in the rabbit. Neurosci. Lett., 21, 345-349.
120. Pfeiffer, C.C., Jenney, E.H. (1957) The inhibition of conditioned responses and the counteraction of schizophrenia by muscarinic stimulation of the brain. Ann. N.Y. Acad. Sci., 66, 753-764.
121. Pierelli, F., Adipietro, A., Soldati, G., Fattaposta, F., Pozzessere, G., Scopetti, C. (1998) Low dosage clozapine effects on L-DOPA-induced dyskinesia in parkinsonian patients. Acta Neurol. Scand., 97, 295-299.
122. Pilowsky, L.S., Costa, D.C., Ell, P.J., Murray, R.M. (1993) Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study. Psychol. Med., 23,791-797.
123. Qian., Y., Hitzemann, B., Hitzemann, R. (1992) D1 and D2 dopamine receptor distribution in the neuroleptic nonresponsive and neuroleptic responsive lines of mice; a quantitative receptor autoradiographic study. J. Pharmacol. Exp. Ther., 261, 341-348.
124. Rabey, J.M., Treves, T.A., Neufeld, M.Y., Orlov, E., Korczyn, A.D. (1995) Low-dose clozapine in the treatment of levodopainduced mental disturbances in Parkinson's disease. Neurology, 45, 432-434.
125. Rasmussen, T., Fink-Jensen, A., Sauerberg, P., Swedberg, M.D., Thomsen, C., Sheardown, M.J., Jeppsen, L., Calligaro, D.O., DeLapp, N.W., Whitesitt, C., Ward, J.S., Shannon, H.E., Bymaster, F.P. (2001) The muscarinic receptor agonist BuTAC, a novel potential antipsychotic, does not impair learning and memory in mouse passive avoidance. Schizophr. Res., 49,193-201.
126. Reisine, T.D., Fields, J.Z., Yamamura, H.I. (1977) Neurotransmitter receptor alterations in Parkinson's disease. Life Sci., 21, 335-344.
127. Richelson, E., Souder, T. (2000) Binding of antipsychotic drugs to human brain receptors. Focus on newer generation compounds. Life Sci., 68,29-39.
128. Roth, B.L., Tandra, S., Burgess, L.H., Sibley, D.R., Meltzer, H.Y. (1995) D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology (Berl.), 120, 365-368.
129. Rowell, F.F., Hui, S.M., Fairburn, A.F., Eccleston, D. (1981) Total and free serum haloperidol levels in schizophrenic patients and the effect of age, thioridazine and fatty acids on haloperidol serum protein binding in vitro. Br. J. Clin. Pharmacol., 11, 377-382.
130. Ruggieri, S., De Pandis, M.F., Bonamartini, A., Vacca, L., Stocchi, F. (1997) Low dose clozapine in the treatment of dopaminergic psychosis in Parkinson's disease. Clin. Neuropharmacol., 20, 204-209.
131. Rylander, G. (1972) Psychoses and the punding and choreiform syndromes in addiction to central stimulant drugs. Psychiatr. Neurol. Neurochir., 75, 203-212.
132. Sanchez-Lemus, E. Arias-Montano, J.A. (2006) M1 muscarinic receptors contribute to, whereas M4 receptors inhibit, dopamine D1 receptor-induced [3H]-cyclic AMP accumulation in rat striatal slices. Neurochem. Res., 31, 555-561.
133. Sassin, J.F. (1975) Drug-Induced Dyskinesias in Monkeys. In: Meldrum, B.S., Marsden, C.D. Eds, Primate Models of Neurological Disorders. (Adv. Neurol., Vol 10), New York, Raven Press, pp. 47-54.
134. Sassin, J.F., Taub, S., Weitzman, E.D. (1972) Hyperkinesia and changes in behaviour produced in normal monkeys by L-dopa. Neurology, 22, 1122-1125.
135. Scatton, B. (1982) Further evidence for the involvement of D2 but not D1 dopamine receptors in dopaminergic control of striatal cholinergic transmission. Life Sci., 31, 2883-2890.
136. Schweitzer, B.I., Bacopoulos, N.G. (1983) Reversible decrease in dopaminergic 3H-agonist binding after 6-hydroxydopamine and irreversible decrease after kainic acid. Life Sci., 32, 531-540.
137. Seeman, P. (1980) Brain dopamine receptors. Pharmacol. Rev., 32, 229-313.
138. Seeman,P. (2002) Atypical antipsychotics: mechanism of action. Can. J. Psychiatry, 47, 27-38.
139. Sesack, S.R., Aoki, C., Pickel, V.M. (1994) Ultrastructural localization of D2 receptor-like immunoreactivity in midbrain dopamine neurons and their striatal target. J. Neurosci., 14, 88-106.
140. Shannon, H.E., Rasmussen, K., Bymaster, F.P., Hart, J.C., Peters, S.C., Swedberg, M.D.B, Jeppesen, L., Sheardown, M.J., Sauerberg, P., Fink-Jensen, A. (2000) Xanomeline, an M1/M4 preferring muscarinic cholinergic receptor agonist, produced antipsychotic-like activity in rats and mice. Schizophr. Res., 42, 249-259.
141. Shen, W., Hamilton, S.E., Nathanson, N.M., Surmeier, J.D. (2005) Cholinergic suppression of KCNQ channel currents enhances excitability of striatal medium spiny neurons. J. Neurosci., 25,7449-7458.
142. Simpson, G.M., Krako, L., Mattke, D., St. Phard, G.S. (1970) A controlled comparison of the treatment of schizophrenic patients when treated according to the neuroleptic threshold or by clinical judgement. Acta Psychiatr. Scand. Suppl., 212, 38-43.
143. Stille, G., Lauener, H., Eichenberger, E. (1971) The pharmacology of 8-chloro-11-(4-methyl-1-piperaninyl) 5-H-dibenzo[b,e]di-azepine (clozapine). FARMACO, 26, 603-625.
144. Stoof, J.C., De Boer, T., Sminia, P., Mulder, A.H. (1982) Stimulation of D2-dopamine receptors in rat neostriatum inhibits the release of acetylcholine and dopamine but does not affect the release of gamma-aminobutyric acid, glutamate or serotonin. Eur. J. Pharmacol., 84, 211-214.
145. Stoof, J.C., Verheijden, P.M.F.H., Leysen, J.E. (1987): Stimulation of D-2 receptors in rat nucleus accumbens slices inhibits dopamine and actylcholine release, but not cyclic AMP formation. Brain Res., 423, 364-368.
146. Sullivan, R.J., Andres, S., Caleb, O., Miles, W., Kydd, R. (2007) The effects of an indigenous muscarinic drug, betal nut (Areca catechu), on the symptoms of schizophrenia: a longitudinal study in Palau, Micronesia. Am. J. Psychiatry, 164, 670-673.
147. Svendsen, C.N., Froimowitz, M., Hrbek, C., Campbell, A., Kula, N., Baldessarini, R.J., Cohen, B.M., Babb, S., Teicher, M.H., Bird, E.D. (1988) Receptor affinity, neurochemistry and behavioral characteristics of the enantiomers of thioridazine: evidence for different stereoselectivities at d1 and d2 receptors in rat brain. Neuropharmacology, 27,1117-1124.
148. Tauscher, J., Küfferle, B., Asenbaum, S., Tauscher-Wisniewski, S., Kasper, S. (2002) Striatal dopamine-2 receptor occupancy as measured with [I123]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotic and haloperidol. Psychopharmacology (Berl.), 162, 42-49.
149. Tauscher, J., Hussain, T., Agid, O., Verhoeff, N.P.L.G., Wilson, A.A., Houle, S., Remington, G., Zipursky, R.B, Kapur, S. (2004) Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am. J. Psychiatry, 161, 1620-1625.
150. The French Clozapine Parkinson Study Group (1999) Clozapine in drug-induced psychosis in Parkinson's disease. Lancet, 353, 2041-2042.
151. The Parkinson Study Group (1999) Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N. Engl. J. Med., 340, 757-763.
152. Togasaki, D.M., Tan, L., Protell, P, Di Monte, D.A., Quik, M., Langston, J.W. (2001) Levodopa induces dyskinesias in normal squirrel monkeys. Ann. Neurol., 50, 254-257.
153. Wang, Z., Kai, L. Ronesi, J., Yin, H.H., Ding, J., Tkatch, T., Lovinger, D.M., Surmeier, D.J. (2006) Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons. Neuron, 50, 443-452.
154. Wiesel, F.-A., Farde, L., Nordström, A.-L., Sedvall, G. (1990) Central D1- and D2-receptor occupancy during antipsychotic drug treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry, 14, 759-767.
155. Wolkin, A., Barouche, F., Wolf, A.P., Rotrosen, J., Fowler, J.S., Shiuo, C.-Y., Cooper, T.B., Brodie, J.D. (1989) Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am. J. Psychiatry, 146, 905.
156. Wong, D.T., Bymaster, F.P., Reid, L.R., Fuller, R.W., Perry, K.W., Kornfeld, E.C. (1983) Effect of a stereospecific D2-dopamine agonist on acetylcholine concentration in corpus striatum in rat brain. J. Neural Transm., 58, 55-67.
157. Wunderink, L., Nienhuis, F.J., Sytema, S., Slooff, C.J., Knegtering, R., Wiersma, D. (2007) Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J. Clin. Psychiatry, 68, 654-661.
158. Yan, Z., Flores-Hernandez, J., Surmeier, J.D. (2001) Coordinated expression of muscarinic receptor mRNAs in striatal medium spiny neurons. Neuroscience, 103, 1017-1024.
159. Zeng, X.P., Le, F., Richelson, E. (1997) Muscarinic M4 receptor activation by some atypical antipsychotic drugs. Eur. J. Pharmacol., 321, 349-354.
160. Zhou, L.-W., Zhang, S.-P., Connell, T.A., Weiss, B. (1993) Cholinergic lesions of mouse striatum induced by AF64A alter D2 dopaminergic behavior and reduced D2 dopamine receptors and D2 dopamine receptor mRNA. Neurochem. Int., 22, 301-311.
161. Zimbroff, D.L., Kane, J.M., Tamminga, C.A., Daniel, D.G., Mack, R.J., Wozniak, P.J., Sebree, T.B., Wallin, B.A., Kashkin, K.B. and the Sertindole Study Group. (1997) Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am. J. Psychiatry, 154,782-791.